You are here

Clinical Trials

Clinical Trials

The Beraprost-314d Added-on to Tyvaso® (BEAT) Study

Beraprost 314d modified release (BPS-314d-MR) is a single isomer prostacyclin analogue oral tablet that is under clinical development. BPS-314d-MR is currently under clinical investigation in a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study. This clinical trial will assess the efficacy and safety of the BPS-314d-MR oral tablet added-on to Tyvaso® (treprostinil) inhalation solution in clinically symptomatic patients with pulmonary arterial hypertension (PAH). More information click here.